# A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

> **NCT05633355** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 187 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Rocatinlimab

## Key facts

- **NCT ID:** NCT05633355
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-30
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05633355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05633355, "A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05633355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*